

Gaucher Disease - Drugs in Development, 2021

<https://marketpublishers.com/r/G06F15F1A7A7EN.html>

Date: November 2021

Pages: 143

Price: US\$ 2,000.00 (Single User License)

ID: G06F15F1A7A7EN

Abstracts

Gaucher Disease - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gaucher Disease - Drugs In Development, 2021, provides an overview of the Gaucher Disease (Genetic Disorders) pipeline landscape.

Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue and seizures. Treatment includes enzyme replacement therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gaucher Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical, Discovery and Unknown

stages are 1, 2, 6, 1, 22, 8 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 6 molecules, respectively.

Gaucher Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Gaucher Disease (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Gaucher Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gaucher Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gaucher Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gaucher Disease (Genetic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gaucher Disease (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gaucher Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Gaucher Disease - Overview

Gaucher Disease - Therapeutics Development

Gaucher Disease - Therapeutics Assessment

Gaucher Disease - Companies Involved in Therapeutics Development

Gaucher Disease - Drug Profiles

Gaucher Disease - Dormant Projects

Gaucher Disease - Discontinued Products

Gaucher Disease - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Gaucher Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Gaucher Disease - Pipeline by Adienne Pharma & Biotech SA, 2021
Gaucher Disease - Pipeline by Apollo Therapeutics LLC, 2021
Gaucher Disease - Pipeline by AVROBIO Inc, 2021
Gaucher Disease - Pipeline by Belrose Pharma Inc, 2021
Gaucher Disease - Pipeline by Bial - Portela & Ca SA, 2021
Gaucher Disease - Pipeline by Bioasis Technologies Inc, 2021
Gaucher Disease - Pipeline by Biosidus SA, 2021
Gaucher Disease - Pipeline by Blue Turtle Bio Technologies Inc, 2021
Gaucher Disease - Pipeline by CANbridge Life Sciences Ltd, 2021
Gaucher Disease - Pipeline by Centogene NV, 2021
Gaucher Disease - Pipeline by Coave Therapeutics, 2021
Gaucher Disease - Pipeline by Denali Therapeutics Inc, 2021
Gaucher Disease - Pipeline by Eli Lilly and Co, 2021
Gaucher Disease - Pipeline by Erad Therapeutics Inc, 2021
Gaucher Disease - Pipeline by Evox Therapeutics Ltd, 2021
Gaucher Disease - Pipeline by Freeline Therapeutics Holdings Plc, 2021
Gaucher Disease - Pipeline by Gain Therapeutics Inc, 2021
Gaucher Disease - Pipeline by Generation Bio Co, 2021
Gaucher Disease - Pipeline by Genzyme Corp, 2021
Gaucher Disease - Pipeline by Graphite Bio Inc, 2021
Gaucher Disease - Pipeline by ILIAS Biologics Inc, 2021
Gaucher Disease - Pipeline by ISU ABXIS Co Ltd, 2021
Gaucher Disease - Pipeline by Johnson & Johnson, 2021

Gaucher Disease - Pipeline by Kashiv BioSciences LLC, 2021
Gaucher Disease - Pipeline by M6P Therapeutics, 2021
Gaucher Disease - Pipeline by Orphazyme A/S, 2021
Gaucher Disease - Pipeline by Recursion Pharmaceuticals Inc, 2021
Gaucher Disease - Pipeline by Sanofi, 2021
Gaucher Disease - Pipeline by SmartPharm Therapeutics Inc, 2021
Gaucher Disease - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Gaucher Disease - Pipeline by Vanqua Bio Inc, 2021
Gaucher Disease - Pipeline by Vera Therapeutics Inc, 2021
Gaucher Disease - Pipeline by Voyager Therapeutics Inc, 2021
Gaucher Disease - Pipeline by Yuhan Corp, 2021
Gaucher Disease - Dormant Projects, 2021
Gaucher Disease - Dormant Projects, 2021 (Contd..1)
Gaucher Disease - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gaucher Disease, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Gaucher Disease - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/G06F15F1A7A7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G06F15F1A7A7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970